Mucositis is a common and vexing complication of autologous progenitor cell transplantation (ABMT). A modified oral mucositis assessment scale (OMAS) has been found to be a reproducible and effective tool for monitoring mucositis after radiation therapy or chemotherapy. We utilized the modified OMAS scale to study clinical parameters associated with the development of mucositis in 79 patients undergoing ABMT. Median patient age was 52; 61% had non-Hodgkin's lymphoma (NHL), 23% multiple myeloma and 14% Hodgkin's disease. Patients were mobilized with G-CSF alone or the combination of etoposide plus G-CSF. Univariable correlates of worse mucositis were prior radiation therapy (P = 0.004), a diagnosis of NHL (P = 0.014), progenitor cell mobilizing regimen containing etoposide (P = 0.001), and ABMT preparative regimen containing etoposide (P = 0.006). Multivariable regression analysis revealed that NHL diagnosis (P = 0.007), prior radiation therapy (P = 0.001), and etoposide in the mobilizing regimen (P = 0.034) were associated with worse post-transplant mucositis. Worsening mucositis correlated with a longer inpatient length of stay. We conclude that several variables contribute to worsening mucositis during autologous transplantation, including etoposide in the progenitor cell mobilizing regimen.
increased days in the hospital, an increased 100 day mortality, and increased hospital charges. 1 Despite widespread acknowledgement that mucositis is a frequent toxicity after autologous transplantation, reports describing factors influencing the incidental severity of mucositis are relatively sparse. A simple and reproducible tool for the evaluation of mucositis, the modified oral mucositis assessment scale (OMAS), 5 has recently been described. Using the modified OMAS scale, we prospectively evaluated 79 consecutive patients from 2000 to 2001 undergoing autologous PBPC transplantation at our institution. We then examined variables associated with the development of mucositis during the transplant, including the PBPC mobilizing regimen.
Patients and methods

Patient characteristics
Seventy-nine consecutive adult patients undergoing autologous PBPC transplantation were included in this analysis. The median age was 52 years; 56 patients (71%) were male. Diagnosis and clinical characteristics are shown in Table 1 . Table 1 Diagnosis and clinical characteristics n % NHL  48  61  Myeloma  18  23  Hodgkin's disease  11  14  Breast cancer  1  1  Germ cell tumor  1  1  Prior radiation therapy  Yes  21  27  No  58  73  Disease status  CR  14  18  PR  54  68  Relapse/NR  11  14  Courses of chemotherapy  1  2 0  2 5  2  4 5  5 7  3 or more  14  18 CR = complete remission; PR = partial remission; NR = non responsive.
Diagnosis
PBPC mobilizing regimens
All patients received one of two mobilizing regimens. Twenty-five patients received G-CSF 10 g/kg/day subcutaneously, with leukopheresis beginning on the 5th day of G-CSF administration. Fifty-four patients received etoposide ((2 g/m   2 ) based on actual weight) plus G-CSF (10 g/kg subcutaneously daily), with leukopheresis beginning once WBC recovery was greater than 1000/mm 3 . Diagnoses of the patients in the two treatment groups are shown in Table 2 . This was a non-randomized study; a higher percentage of patients with non-Hodgkin's lymphoma (NHL) received etoposide plus G-CSF largely because a significant percentage of these patients had actively growing disease and the combination of etoposide plus G-CSF was used to secure disease control pre-transplant.
Preparative regimen
The majority of patients received a preparative regimen of busulfan, cyclophosphamide, etoposide (busulfan 14 mg/kg, etoposide 60 mg/kg and cyclophosphamide 120 mg/kg) or busulfan-cyclophosphamide (busulfan 16 mg/kg, cyclophosphamide 120 mg/kg) as shown in 
PBPC collection and processing
Most patients were apheresed for 3-5 days, with a minimum yield of CD34 + cells of 2.0 ϫ 10 6 CD34 + cells/kg. PBPC collection was performed on a COBE spectra leukopheresis machine (COBE, Denver, CO, USA).
Supportive care
Patients were hospitalized for the delivery of chemotherapy and discharged after adequate hematologic recovery Table 2 PBPC mobilization regimen occurred. Platelet or RBC transfusions were administered when the platelet count was less than 15 000 10 9 /l or hemoglobin was less than 8.5 g/dl, respectively. All blood products were irradiated before infusion. Broad-spectrum antibiotics were administered for febrile neutropenic episodes.
Mucositis assessment
We used the modified OMAS tool to evaluate mucositis. The OMAS scale evaluates multiple regions of the oral cavity for erythema (none, mild, moderate, severe) and the presence of ulcerations or pseudomembranes. The scale ranges from 0 to 2.0, with a score of 0.5 or greater considered to be significant for severe mucositis. Table 3 shows a copy of the modified OMAS tool.
Mucositis was prospectively assessed by one of three physician assistants (RL, JK, SM) for all patients. Patients were assessed Mondays, Wednesdays and Fridays. The highest OMAS score was used for analysis.
Statistical analysis
The association of the mucositis with categorical variables was assessed using either the t-test or analysis of variance. Stepwise multiple linear regression analysis was used to identify multivariable correlates of mucositis; results of the multiple regression analysis are shown as the parameter estimate, standard error, and corresponding P value. The variables that were considered as potential correlates of mucositis were age, gender, actual body weight, ratio of actual to ideal body weight, diagnosis, prior radiation therapy, number of courses of chemotherapy, preparative regimen, and mobilization regimen. In all analyses, mucositis was measured via OMAS and assessed as a continuous variable. P Ͻ 0.05 was used to indicate statistical significance for all analyses. Only the statistically significant findings are reported.
Results
Mucositis was common, with a mean OMAS score of 0.77 for the entire group (range 0.00-1.92). Fifty-two patients (66%) experienced severe mucositis (OMAS score of у0.5). Mean inpatient length of stay for the entire group was 23 days (range 19-57 days).
Univariable correlates of OMAS are shown in Table 4 . Diagnosis, prior radiation therapy, ABMT preparative regimen containing etoposide, and etoposide in the mobilizing regimen correlated with OMAS. Of the three most common diagnoses, multiple myeloma patients had the lowest mean OMAS and NHL patients had the highest.
Multivariable analysis revealed that prior radiation therapy, a diagnosis of NHL, and etoposide in the mobilizing regimen contributed to worse mucositis, as shown in Table  5 . After adjustment for a diagnosis of NHL in the analysis, Table 5 Multiple linear regression analysis Figure 1 shows a box plot of mucositis and the two mobilizing regimens.
Variable
Of the 21 patients receiving prior radiation therapy, 12 received radiation therapy to sites above the diaphram and nine to sites below the diaphram. We defined these two groups as 'proximal' and 'distal' radiation therapy. Those receiving proximal radiation therapy had a mucositis score 0.48 units higher than if no radiation therapy was delivered; patients receiving distal radiation therapy developed a mucositis score that was 0.29 units higher than if no radiation therapy was given. We repeated the multivariable analysis using proximal and distal radiation therapy in the model, and found that proximal radiation therapy was highly correlated with the development of mucositis, (P = 0.002) and distal radiation therapy also correlated, although not to statistical significance (P = 0.09).
Worsening mucositis correlated with a longer inpatient length of stay. Patients with a maximum OMAS score of 1.0 or less had a mean stay of 21 days, vs 27 days for those with an OMAS score of greater than 1.0 (P Ͻ0.001, t-test).
Discussion
Etoposide plus G-CSF is an excellent PBPC mobilizing regimen. [6] [7] [8] The most common toxicity reported is transient neutropenia. Etoposide has also been widely described to be an effective agent as part of an ablative ABMT preparative regimen. The dose limiting non-hematologic toxicity of high-dose etoposide is mucositis, 9,10 and most ABMT regimens using etoposide have noted a significant incidence of mucositis. [11] [12] [13] [14] [15] [16] [17] We were somewhat surprised that any variable used in the PBPC mobilizing regimen influenced mucositis post transplant. Generally, etoposide administration for PBPC mobilization was approximately 3 weeks prior to the initiation of the ABMT preparative regimen. The fact that the use of etoposide in the mobilization regimen was a significant variable in the development of mucositis despite its use weeks before the transplant, suggests that prior eto- The use of total body radiation in the ABMT preparative regimen has been reported to correlate with mucositis post transplant. Our results showed that any prior exposure to radiotherapy contributed to worse mucositis post transplant. Not surprisingly, radiation therapy delivered above the diaphram correlated with mucositis; somewhat surprisingly, distant radiation therapy exposure showed a trend towards worsening mucositis as well.
The major limitation of this trial was the fact that the mobilizing groups were non-randomized. Whether etoposide as part of the mobilizing regimen contributes to mucositis post ABMT should be confirmed in subsequent controlled clinical trials. NHL patients generally received more pre-BMT therapy which may also have confounded our results.
We confirmed prior observations that worsening mucositis contributes to a longer inpatient length of stay. The fact that patients with an OMAS score of Ͼ1.0 had a length of stay lengthened by 6 days (29% longer) reflects the importance of mucositis for these patients.
The treatment and prevention of mucositis has been a difficult challenge. While small trials have reported favorable outcomes using anticholinergic agents, 18 prostaglandins 19 and topical antibiotics, [20] [21] [22] there has been no clear-cut standard of care defined to prevent severe mucositis in transplant patients. More recently, trials involving protegrins, 23, 24 which are naturally occurring antimicrobial peptides, have shown excellent promise in phase II trials. Additionally, recombinant human keratinocyte growth factor has shown promising efficacy in reducing mucositis in autologous ABMT patients. 25 Hopefully, these promising phase II data will be confirmed in phase III trials and reduce the incidence and severity of mucositis for ABMT patients. 
